Gossamer Bio submits first NDA, for seralutinib in PAH, to FDANov 10Quarterly updateGossamer Bio, Inc.seralutinib
Gossamer Bio ends open-label extension study of inhaled seralutinib for PAHOct 7Trial updateGossamer Bio, Inc.seralutinib
Gossamer Bio submits first NDA, for seralutinib in pulmonary arterial hypertensionSep 23Regulatory milestoneGossamer Bio, Inc.seralutinib
Gossamer Bio adds Greg Ciongoli to board and audit committeeSep 16PeopleGossamer Bio, Inc.seralutinib
Gossamer Bio secures up to $250 million private placement tied to seralutinib milestonesAug 21FinancingGossamer Bio, Inc.seralutinib
Gossamer reports Q2 2026 results, reacquires seralutinib rights from ChiesiAug 13Quarterly updateGossamer Bio, Inc.seralutinib
Gossamer Bio reacquires worldwide seralutinib rights from Chiesi, targets September NDAJul 27Regulatory milestoneGossamer Bio, Inc.seralutinib